Skip to main content

Table 5 p53 status and prognosis of colorectal cancer: comparison between literature deta and the present report

From: Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Reference n Histology treatment Methods for determing p53 Ab IHC Sequencing Frequency of alterd p53 pathway (%) Prognostic value Event-free survival Response
Overall survial
Popat S [22] 967 CRC Adjuvant - + - 60 (IHC) NS NA NA
Zaana A [23] 233 CRC Adjuvant - + - 53 (IHC) NA NS NA
Ahn MJ [24] 45 mCRC chemotherapy - + - 80 (IHC) NA NA NS
Berglund A [25] 122 mCRC chemotherapy - + - 60 (IHC) NS NA NS
Ince WL [26] 295 CRC chemotherapy - + + 68 (IHC), 72(S) NS, NS NA NA
Mollevi DG [27] 91 mCRC chemotherapy - - + 50.5 (S) multivariate NA NA
Rosty C [28] 56 mCRC chemotherapy - - + 62.5 (S) univariate NA NS
Westra JL [29] 220 CRC Adjuvant - - + 53(S) NA murtivariate NA
Oden-Gangloff [30] 64 mCRC chemotherapy - - + 64(S) NA murtivariate NA
Present study 90 mCRC chemotharapy + + - 40(Ab), 63(IHC) NS,NS NS,NS NS,NS
  1. Ab antibody; IHC immunohistochemistry; S sequencing; (m)CRC (metastatic) colorectal cancer; NA not available; NS not significant